Patient-reported outcomes after personalised dose-escalation for stage II-III non-small-cell lung cancer patients: Results from the randomised ARTFORCE PET-Boost trial

CONCLUSION: In patients with LA-NSCLC treated with two dose-escalation strategies, the average patient-reported HRQoL remained stable in both groups, despite frequent patient-reported symptoms, including dyspnoea, dysphagia, and fatigue.PMID:38663582 | DOI:10.1016/j.radonc.2024.110312

Source: Radiotherapy and Oncology : journal of the European Society for Therapeutic Radiology and Oncology - April 25, 2024 Category: Radiology Authors: Saskia A Cooke Jos é S A Belderbos Bart Reymen Maarten Lambrecht Gitte Fredberg Persson Corinne Faivre-Finn Edith M T Dieleman Judi N A van Diessen Jan-Jakob Sonke Dirk de Ruysscher Source Type: research